Population
Heart transplant recipients at risk for or developing coronary allograft vasculopathy (CAV)
Design
Review
Authors
Loading...
Experimental antisense ODN data for CAV remain hypothesis-generating; clinical gene therapy translation requires prospective trials.
This review highlights the pathogenesis of coronary allograft vasculopathy and the potential of antisense oligodeoxynucleotides as a future gene therapy for its prevention.
Suzuki et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: